ProfileGDS5678 / 1433801_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 55% 62% 62% 61% 57% 58% 60% 61% 61% 65% 72% 62% 61% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4099555
GSM967853U87-EV human glioblastoma xenograft - Control 23.6784562
GSM967854U87-EV human glioblastoma xenograft - Control 33.6777362
GSM967855U87-EV human glioblastoma xenograft - Control 43.630161
GSM967856U87-EV human glioblastoma xenograft - Control 53.3970657
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5748758
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6748760
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6608761
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6611861
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9065365
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6154872
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6752462
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6763761
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7048962